Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 78 citing articles:

A comprehensive review on adult onset Still's disease
Roberto Giacomelli, Piero Ruscitti, Yehuda Shoenfeld
Journal of Autoimmunity (2018) Vol. 93, pp. 24-36
Closed Access | Times Cited: 345
Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies
Petros Efthimiou, Apostolos Kontzias, Peter Hur, et al.
Seminars in Arthritis and Rheumatism (2021) Vol. 51, Iss. 4, pp. 858-874
Open Access | Times Cited: 139
Recent advances and evolving concepts in Still’s disease
Piero Ruscitti, Luca Cantarini, Peter A. Nigrović, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 116-132
Closed Access | Times Cited: 30
EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease
Bruno Fautrel, Stéphane Mitrovic, Arianna De Matteis, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 12, pp. 1614-1627
Closed Access | Times Cited: 26
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm
Piero Ruscitti, Onorina Berardicurti, Paola Di Benedetto, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 95
SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment
Marcella Prete, Elvira Favoino, Giacomo Catacchio, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3377-3377
Open Access | Times Cited: 85
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations
Piero Ruscitti, Paola Di Benedetto, Onorina Berardicurti, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 52
The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature
Roberto Giacomelli, Jurgen Sota, Piero Ruscitti, et al.
Clinical and Experimental Rheumatology (2021) Vol. 39, Iss. 1, pp. 187-195
Open Access | Times Cited: 47
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
Elvira Favoino, Marcella Prete, Giacomo Catacchio, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 3, pp. 102750-102750
Closed Access | Times Cited: 42
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences
Piero Ruscitti, Federico Bruno, Onorina Berardicurti, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 9, pp. 1152-1155
Open Access | Times Cited: 45
Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients
Piero Ruscitti, Onorina Berardicurti, Daniela Iacono, et al.
Arthritis Research & Therapy (2020) Vol. 22, Iss. 1
Open Access | Times Cited: 44
Tocilizumab for the treatment of adult-onset Still’s disease
Santos Castañeda, Dolores Martínez-Quintanilla, J. L. Martín-Varillas, et al.
Expert Opinion on Biological Therapy (2019) Vol. 19, Iss. 4, pp. 273-286
Open Access | Times Cited: 43
Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still’s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort
Paola Di Benedetto, Paola Cipriani, Daniela Iacono, et al.
PLoS ONE (2020) Vol. 15, Iss. 7, pp. e0235326-e0235326
Open Access | Times Cited: 43
Latent class analysis of 216 patients with adult-onset Still’s disease
Takahiro Sugiyama, Shunsuke Furuta, Masaki Hiraguri, et al.
Arthritis Research & Therapy (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 24
Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus
Piero Ruscitti, Yannick Allanore, Chiara Baldini, et al.
Autoimmunity Reviews (2024) Vol. 23, Iss. 7-8, pp. 103581-103581
Closed Access | Times Cited: 5
Pathogenesis of adult onset still’s disease: current understanding and new insights
Piero Ruscitti, Roberto Giacomelli
Expert Review of Clinical Immunology (2018) Vol. 14, Iss. 11, pp. 965-976
Closed Access | Times Cited: 44
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study
Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli, et al.
Medicine (2019) Vol. 98, Iss. 15, pp. e15123-e15123
Open Access | Times Cited: 39
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still’s disease
Piero Ruscitti, Francesco Ursini, Onorina Berardicurti, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 1, pp. 321-329
Closed Access | Times Cited: 21
The Systemic Score May Identify Life‐Threatening Evolution in Still Disease: Data from the GIRRCS AOSD‐Study Group and the AIDA Network Still Disease Registry
Piero Ruscitti, Francesco Masedu, Antonio Vitale, et al.
Arthritis & Rheumatology (2024) Vol. 76, Iss. 7, pp. 1141-1152
Closed Access | Times Cited: 4
Dissecting the clinical heterogeneity of adult-onset Still’s disease: results from a multi-dimensional characterization and stratification
Onorina Berardicurti, Alessandro Conforti, Daniela Iacono, et al.
Lara D. Veeken (2020) Vol. 60, Iss. 10, pp. 4844-4849
Closed Access | Times Cited: 32
The Pathogenic Role of Interferons in the Hyperinflammatory Response on Adult-Onset Still’s Disease and Macrophage Activation Syndrome: Paving the Way towards New Therapeutic Targets
Ilenia Di Cola, Piero Ruscitti, Roberto Giacomelli, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 6, pp. 1164-1164
Open Access | Times Cited: 22
Detection and Prediction of Macrophage Activation Syndrome in Still’s Disease
Clément Javaux, T. El-Jammal, Pierre-Antoine Neau, et al.
Journal of Clinical Medicine (2021) Vol. 11, Iss. 1, pp. 206-206
Open Access | Times Cited: 22
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry
Piero Ruscitti, Francesco Masedu, Antonio Vitale, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e003419-e003419
Open Access | Times Cited: 9
Characteristics of Circulating Natural Killer Cells and Their Interferon-γ Production in Active Adult-onset Still Disease
Yasuhiro Shimojima, Dai Kishida, Ken‐ichi Ueno, et al.
The Journal of Rheumatology (2019) Vol. 46, Iss. 10, pp. 1268-1276
Closed Access | Times Cited: 25
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort
Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli, et al.
Rheumatology International (2019) Vol. 40, Iss. 1, pp. 107-113
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top